Alberto Enrico Maraolo1, Adriano Grossi2. 1. First Division of Infectious Diseases, Cotugno Hospital, Naples, Italy. 2. Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italy.
Abstract
INTRODUCTION: Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. METHODS: In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials. RESULTS: Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45. CONCLUSION: Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.
INTRODUCTION: Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. METHODS: In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials. RESULTS: Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45. CONCLUSION: Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.
Authors: Alexandre B Cavalcanti; Fernando G Zampieri; Regis G Rosa; Luciano C P Azevedo; Viviane C Veiga; Alvaro Avezum; Lucas P Damiani; Aline Marcadenti; Letícia Kawano-Dourado; Thiago Lisboa; Debora L M Junqueira; Pedro G M de Barros E Silva; Lucas Tramujas; Erlon O Abreu-Silva; Ligia N Laranjeira; Aline T Soares; Leandro S Echenique; Adriano J Pereira; Flávio G R Freitas; Otávio C E Gebara; Vicente C S Dantas; Remo H M Furtado; Eveline P Milan; Nicole A Golin; Fábio F Cardoso; Israel S Maia; Conrado R Hoffmann Filho; Adrian P M Kormann; Roberto B Amazonas; Monalisa F Bocchi de Oliveira; Ary Serpa-Neto; Maicon Falavigna; Renato D Lopes; Flávia R Machado; Otavio Berwanger Journal: N Engl J Med Date: 2020-07-23 Impact factor: 91.245
Authors: David R Boulware; Matthew F Pullen; Ananta S Bangdiwala; Katelyn A Pastick; Sarah M Lofgren; Elizabeth C Okafor; Caleb P Skipper; Alanna A Nascene; Melanie R Nicol; Mahsa Abassi; Nicole W Engen; Matthew P Cheng; Derek LaBar; Sylvain A Lother; Lauren J MacKenzie; Glen Drobot; Nicole Marten; Ryan Zarychanski; Lauren E Kelly; Ilan S Schwartz; Emily G McDonald; Radha Rajasingham; Todd C Lee; Kathy H Hullsiek Journal: N Engl J Med Date: 2020-06-03 Impact factor: 91.245
Authors: Caleb P Skipper; Katelyn A Pastick; Nicole W Engen; Ananta S Bangdiwala; Mahsa Abassi; Sarah M Lofgren; Darlisha A Williams; Elizabeth C Okafor; Matthew F Pullen; Melanie R Nicol; Alanna A Nascene; Kathy H Hullsiek; Matthew P Cheng; Darlette Luke; Sylvain A Lother; Lauren J MacKenzie; Glen Drobot; Lauren E Kelly; Ilan S Schwartz; Ryan Zarychanski; Emily G McDonald; Todd C Lee; Radha Rajasingham; David R Boulware Journal: Ann Intern Med Date: 2020-07-16 Impact factor: 25.391
Authors: Gongxin Wang; Chieh-Ju Lu; Andrew W Trafford; Xiaohui Tian; Hannali M Flores; Piotr Maj; Kevin Zhang; Yanhong Niu; Luxi Wang; Yimei Du; Xinying Ji; Yanfang Xu; Lin Wu; Dan Li; Neil Herring; David Paterson; Christopher L-H Huang; Henggui Zhang; Ming Lei; Guoliang Hao Journal: ACS Pharmacol Transl Sci Date: 2021-08-30